# A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Source: https://onco.cc/trials/nct06319963/  
OnCo record `nct06319963` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Two IM injections Lenti-HPV-07 in cervical cancer and head and neck squamous cell carcinoma, run by Theravectys S.A., now recruiting.

## Summary

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer is a phase 1/2 interventional study registered as NCT06319963 by Theravectys S.A., with 72 participants planned, started 2024-08-08 and due to reach its primary completion in 2026-06. Interventions recorded: Two IM injections Lenti-HPV-07 and One IM injection Lenti-HPV-07.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06319963
- Phase: 1/2
- Setting: An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
- Sponsor: Theravectys S.A.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT06319963: https://clinicaltrials.gov/study/NCT06319963

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)

---
JSON: https://onco.cc/api/v1/entities/nct06319963.json